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Abstract
Background: Interleukin (IL)-27, which has both pro and anti- inflammatory properties, is a new discovered
heterodimeric cytokine that belongs to IL-12 family. However, the expression pattern and functional role of IL-27
in viral myocarditis (VMC) has not been investigated.
Methods: BALB/c mice were intraperitoneally (i.p) infected with Coxsackie virus B3 (CVB3) for establishing VMC
models. Mice were then injected i.p. with Anti-Mouse IL-27 p28Ab or recombinant IL-27 for neutralization and
overexpression of IL-27. The survival rates of mice were recorded and the kinetics of IL-27 expression, the frequencies
of Th17 cells and the expression of inflammatory cytokine in CVB3-infected mice were determined by ELISA, real-time
PCR and flow cytometry.
Results: The IL-27 expression in heart tissues and serum in coxsackievirus B3 (CVB3)-induced myocarditis mice peaked
on day 4 but then rapidly decreased during the late infectious stage of CVB3, high IL-27 levels were negatively
correlated with bodyweight loss (r = −0.71, P = 0.021) and myocardial pathological score (r = −0.85, P = 0.0018).
Additionally, neutralization of IL-27 with Anti-IL-27 Ab accelerated, whereas systemic administration of recombinant
mouse IL-27 ameliorated CVB3-induced myocarditis. The protective role of IL-27 in VMC was reflected by an improved
survival rate, increased bodyweights, and reduced pathological scores in Anti-IL-27 group compared with IgG control
group. Mechanistic investigations showed that IL-27 inhibited Th17 cells frequencies and IL-17 production, as well as
the Th17-related proinflammatory cytokines in heart tissues.
Conclusions: Our results demonstrate that that IL-27 effectively protects the myocardium from the pathogenesis of
CVB3 induced myocarditis, which may be attributable to reduced Th17 production. IL-27 might serve as a novel
therapeutic treatment for VMC.
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Background
Viral myocarditis (VMC), which was characterized by
myocardial inflammation and can progress to acute
myocarditis, chronic dilated cardiomyopathy and even
congestive heart failure, has been recognized as a com-
mon cause of abrupt death in young adults [1]. Cox-
sackie virus B3 (CVB3), an enteric virus of the
Picornaviridae family, is thought to be the leading cause
of VMC [2]. Accumulating evidence had indicated that
excessively activated inflammation and autoimmune re-
sponses triggered by the viral infection, rather than direct
viral infection, are the dominant causes of myocardial cells
damage in VMC [3, 4]. Emerging evidences have revealed
that several T helper (Th) subsets, such as Th1, Treg and
Th17 cells, are involved in the pathogenesis of VMC [5].
However, the fundamental mechanisms responsible for
VMC remain largely unknown.
IL-27 is a newly discovered heterodimeric cytokine
that belongs to IL-12 family, which is composed of the
Epstein-Barr virus-induced gene 3 (EBI3) and the p28
subunit [6]. IL-27 signals through a receptor composed
of the common IL-6 receptor chain gp130, used by
* Correspondence: Dr_pliu@126.com
3Department of Cardiology, Xianyang Hospital of Yan’an University, No 38
Wenlin Raod, Xianyang 712000, Shaanxi, China
Full list of author information is available at the end of the article
© 2015 Zhu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhu et al. Virology Journal  (2015) 12:189 
DOI 10.1186/s12985-015-0418-x
several other IL-6 and IL-12 family members, and a
unique IL-27 receptor α chain (IL-27RA) homologous to
the IL-12Rβ2 chain of the IL-12 receptor [7]. IL-27 is
produced by dendritic cells, monocytes and endothelial
cells. Its receptor has been found on various cell types
such as T cell subsets, NK cells, NK T cells, dendritic
cells, B cells and mast cells [8]. IL-27 plays a critical role
in the early regulation of T helper type 1 initiation, and
enhances proliferation of naive CD4+T cells and naive B
cells [9–11]. It, however, also exerts anti-inflammatory
functions by inhibiting the development of Th17 cells
and inducing IL-10 producing type 1 regulatory T cells
[12–14]. Thus, IL-27 plays both pathogenic and pro-
tective roles in given infection and autoimmune disease
models.
IL-27 was found recently to be a novel anti-HIV cyto-
kine that inhibits HIV-1 replication in both CD4+T cells
and macrophages [15, 16]. However, the presence of IL-
27 in VMC has not been evaluated. The role of IL-27 in
the pathogenesis of VMC is still unclear. In this study,
we examined the potential effects of IL-27 on VMC
using a murine model of VMC induced by CVB3. The
kinetics of IL-27 expression, the frequencies of Th17
cells and the expression of inflammatory cytokine in
CVB3-infected mice were determined; neutralizing anti-
IL-27 antibodies were used to CVB3-infected mice and
the therapeutic effects of this strategy on viral myocardi-
tis were assessed.
Results
Expression of IL-27 and IL-27R in VMC
To generate an acute viral myocarditis model, male
BALB/c mice were injected i.p. with 103 TCID50 of
CVB3, as described previously [17, 18]. As expected, the
signs of VMC were apparent in CVB3-infected mice, in-
cluding weakness, coat ruffling, irritability, back arching,
lethargy, anorexia and weight loss. The bodyweights of
the CVB3-infected mice decreased continuously from day
4 post-infection compared with those of control mice
(Fig. 1a). In addition, the myocarditis scores of heart sec-
tions showed slight myocardial injury on day 4, but
increased obviously in subsequent days (Fig. 1b). In
contrast, the myocarditis viral replication (positive strand
of CVB3) was detected on day 2; the viral loads (negative-
strand of CVB3) peaked on day 4 and rapidly decreased
subsequently. On day 7, the viral replication and loads
have been dropped to very low levels (Fig. 1c), suggesting
that viral infection was not the dominant causes of myo-
cardial cells damage in VMC. We also monitored the ani-
mal’s survival after CVB3 infection. 8 of 20 (40 %) mice
died in the VMC group. Specifically, on day 6, 7, 8, 10, 11
post infection, there were 1, 1, 2, 2, 2 mice dead in the
VMC group. In contrast, none of mice died in the control
group (Fig. 1d).
We then examined the kinetic expression of IL-27
after CVB3 infection. As shown in Fig. 1e and f, plasma
IL-27p28 levels and IL-27 protein in cardiac tissues
peaked on day 4 but then rapidly decreased during the
late infectious stage of CVB3, and the significantly in-
creased level of the IL-27 protein and gene transcripts in
the VMC group were observed compared with those in
the control group during infectious stage of CVB3 from
day 2 (Fig. 1e and f). Additionally, the relative gene and
protein expression of IL-27RA, the specific receptor of
IL-27, was obviously up-regulated in the VMC group,
compared with that in the control group on day 7 post
infection (Fig. 1g and h).
Association between IL-27 expression and disease
severity in VMC
To further investigate the role of IL-27 in the patho-
logical processes of VMC, the correlation between IL-27
expression and disease activity, including bodyweight
loss and myocardial score were analyzed on day 7 post
CVB3 infection. As shown in Fig. 2a and b. The IL-27
gene transcripts level in cardiac tissues was negatively
correlated with bodyweight loss (r = −0.71, P = 0.021)
and the myocardial pathological score (r = −0.85, P =
0.0018). Similar results were observed for the serum IL-
27 levels (Fig. 2c and d), suggesting that IL-27 may exert
a protective effect against CVB3-induced myocarditis.
Neutralization of IL-27 exacerbated while administration
of rmIL-27 alleviated CVB3-induced myocarditis
Next, we examined the protective role of IL-27 against
CVB3-induced myocarditis in vivo. As shown in Fig. 3,
the results showed that neutralization of IL-27 with
Anti-IL-27 Ab accelerated the development of myocardi-
tis and exacerbated the severity, whereas the administra-
tion of rmIL-27 ameliorated CVB3-induced myocarditis.
Firstly, the survival rate of the Anti-IL-27 group was sig-
nificantly declined compared with those in IgG control
groups (P = 0.024), while mice treated with rmIL-27
group exhibited improved survival rate compared with
those in PBS control group (P = 0.031, Fig. 3a). Addition-
ally, mice treated with Anti-IL-27 underwent marked
and continuous bodyweight loss, while mice received
rmIL-27 showed slightly bodyweight loss (Fig. 3b). Con-
sistent with these findings, the pathological myocarditis
scores of heart sections were higher in mice receiving
Anti-IL-27Ab than those IgG control group, and were
lower in mice received rmIL-27compared with those in
PBS control group (Fig. 3c and d). There were no signifi-
cant differences between PBS and IgG control groups re-
garding the survival rates, bodyweight loss and cardiac
pathological scores.
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IL-27 ameliorates CVB3-induced myocarditis by inhibiting
Th17 cells
Accumulating evidence had indicated that Th17 cells
play an important role in the pathogenesis of CVB3-
inducedmyocarditis [19, 20]. Moreover, IL-27 had been
reported to be a potent inhibitor of Th17 cells [12].
Therefore, we first explored the splenic Th17 frequen-
cies, the characteristic cytokines, and the transcription
factor in cardiac tissues on day 7 after CVB3 infection.
As shown in Fig. 4a and b, the percentage of Th17 cells
in Anti-IL-27 Ab group was higher than those in IgG
control group, and reduced two fold by rmIL-27 treat-
ment compared with those in PBS control group. Similar
results were observed for the Th17-associated cytokines
(IL-17A and IL-22) and the master transcription factor
ROR-γt gene expressions in cardiac tissues (Fig. 4c).
Activated inflammation triggered by excessive proin-
flammatory cytokines are the dominant causes of myo-
cardial cells damage in VMC [3]. Thus we further
examined the proinflammatory cytokines levels, such as
IL-17A, IFN-γ, IL-6, and TNF-α in serum by ELISA. As
shown in Fig. 4d, compared with those in IgG control
groups, the levels of IL-17A, TNF-α and IL-6 proteins
levels were increased dramatically in the Anti-IL-27 Ab
group. In addition, significantly lower levels of IL-17A,
IL-6, and TNF-α expression were seen in mice treated
with rmIL-27. However, the levels of IFN-γ in the Anti-
IL-27 Ab group were also higher than those IgG control
Fig. 1 Expression kinetics of IL-27 and IL-27R in VMC. Male BALB/c mice were infected with 103 TCID50 of CVB3 at day 0. a Body weight was
monitored daily until day 10 post-infection. b The severity of myocarditis was scored every 2 days until day 10 post-infection using a scale
based on foci of mononuclear infiltration and myocardial necrosis. c The myocarditis viral replication (positive strand of CVB3) and the viral
loads (negative-strand of CVB3) were detected using qRT-PCR. d The survival rate of CVB3-infected mice and control mice after CVB3 infection
were recorded (n = 20 per group). The expression of IL-27 in serum (e) and cardiac tissue (f) were monitored every two days until day 10 post-
infection by ELISA assay. The expression of IL-27R mRNA (g) and protein (h) levels in cardiac tissue on day 7 post infection. Data are showed
as the means ± SEM, Each time point contained three mice. ***P<0.001
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Fig. 3 Neutralization of IL-27 exacerbated while administration of rmIL-27 alleviated CVB3-induced myocarditis. Male BALB/c mice were infected
with 103 TCID50 of CVB3 at day 0; mice were injected i.p. with IL-27 p28Ab or rmIL-27 on day 0 and 5 after CVB3 infection. The survival rates (a),
body weight (b) and the severity of myocarditis (c and d) were monitored. Each group contained ten mice. Results are presented as the mean ±
SEM of three independent experiments. *P<0.05, **P<0.01, ***P<0.001, compared with PBS group; #P<0.05, ##P<0.01, compared with IgG group
Fig. 2 Association between IL-27 expression and disease severity in VMC. Male BALB/c mice (n = 10) were infected with 103 TCID50 of CVB3 at
day 0. IL-27 expression levels in cardiac tissues were negatively correlated with body weight loss (a) and myocarditis pathological score (b) on
day 7 post-infection. IL-37 expression levels in serum were negatively correlated with body weight loss (c) and myocarditis pathological score (d)
on day 7 post-infection
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group, and no significant difference was detected be-
tween rmIL-27 treatment group and PBS control group.
Discussion
IL-27 has both pro- and anti-inflammatory functions. It
can activate STAT1 in naive CD4+ T cells, stimulate their
proliferation and induce Th1 cell differentiation [21].
However, it also suppresses immune responses through
inhibition of the development of Th17 cells and induction
of IL-10 production by regulatory Tr1 cells in a STAT1-
and STAT3-dependent manner [12, 14]. Therefore, its role
in VMC, if any, was difficult to predict.
Here we report that IL-27 plays an important role in
the pathogenesis of VMC in a CVB3-induced myocardi-
tis mouse model. We initially observed that IL-27 was
produced during the infectious stage of CVB3. Its levels
in serum and cardiac tissues peaked at day 4 and rapidly
dropped during the late infectious stage. In line with the
kinetics of IL-27 production, the relative gene and pro-
tein expression of IL-27RA, the specific receptor of IL-
27, was also obviously up-regulated during the infectious
stage of CVB3. However, IL-27 exhibited low expression
levels and no alteration in the serum and cardiac tissues
in control mice, indicating that IL-27 may not contribute
to the initiation of VMC. To our knowledge, this obser-
vation provides the first demonstration of an association
of increased IL-27 serum and cardiac tissues levels and
CVB3-induced myocarditis. Furthermore, it is striking that
the severity of VMC negatively correlated with serum and
cardiac levels of IL-27, suggesting that IL-27 may exert a
protective effect against CVB3-induced myocarditis.
Based on the observation that levels of IL-27 and IL-
27 receptor were elevated in VMC, as well as the nega-
tive association between IL-27 levels and the severity of
VMC, we examined the efficacy of IL-27 in the VMC
mouse model, with the use of anti- IL-27 antibody and
recombinant mouse IL-27, respectively. Our results
proved that neutralization of IL-27 exacerbated the se-
verity of CVB3-induced VMC, which was verified by
the lower survive rate, continuous bodyweight loss and
higher values of pathological myocarditis scores. On
the other hand, administration of rmIL-27 significantly
alleviated the severity of CVB3-induced VMC in mice,
with reduced cardiac injury and an improved survival
rate. Interestingly, rmL-27 did not affect the body
weight loss and survival in mice not-infected with the
CVB3, suggesting that IL-27 itself have no effect on the
immune responses in naïve mouse (Additional file 1:
Fig. 4 IL-27 ameliorates CVB3-induced myocarditis by inhibiting Th17 cells. a Representative FACS profile of Th17 cells in the spleen of CVB3 infection
mice treated with rmIL-27 or Anti-IL-27 on day 7 post infection. Cells were gated on CD3+CD4+ T cells. b Statistical analysis of the percentage of Th17
cells. c Expression of Th17 cells characteristic cytokines, IL-17A, IL-22, and key transcription factor ROR-γt in cardiac tissues on day 7 after CVB3 infection
were detected by qRT-PCR. d The serum levels of proinflammatory cytokines IL-17A, IFN-γ, IL-6 and TNF-α in CVB3 infection mice were determined by
ELISA. Normal, mice not-infected with the virus. Data are showed as the means ± SEM. *P<0.05, **P<0.01, ***P<0.001
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Figure S1). Taken together, our results indicate that IL-27
could be a therapeutic cytokine for the treatment of viral
myocarditis as well as other inflammatory diseases.
It is well known that the bias of the T-cell immune
response markedly affects the severity of myocarditis.
Fierce Th1 immune responses play a critical pathogen-
etic role in the course of VMC, especially in the sub-
acute stage (days 4–14). However, increasing recent
evidences indicate that besides Th1 cells, Th17 cells are
also involved in the pathogenesis of VMC. Blockade of
IL-17A increases the number of Th1 and CD8+T cells
and IFN-γ levels, while decreases Treg cells and serum
levels of IL-6, IL-10, IL-2, and IL-21, which ameliorates
the pathological cardiac changes and reduces viral replica-
tion [19, 20, 22]. Interestingly, the induction of distinct
Th17 populations contributes to sex based differences in
the susceptibility to CVB3-induced myocarditis [18]. In
addition, there are several reports demonstrated that IL-
27 suppresses Th17 responses. IL-27 suppresses IL-17
production from CD4+ T cells stimulated with α-CD3/
CD28, IL-6, and TGF-β via mainly STAT1-dependent
[13]. IL-27 also suppresses production of IL-22, which is
important for Th17 effector function [23, 24]. Thus we
speculate that IL-27 may contribute to the alleviation of
CVB3-induced myocarditis through modulating Th17
cells responses.
In the present study, we observed a reduction in Th17
cells in the spleens of infected mice after rmIL-27 treat-
ment in vivo. Th17-associated cytokines (IL-17A and
IL-22) and the master transcription factor ROR-γt gene
expressions in cardiac tissues were also noticeably de-
creased after rmIL-27 treatment. We also observed in-
creased Th1 cells in the spleen after IL-27 treatment
(data not shown). Additionally, serum levels of IL-17A,
TNF-α and IL-6 were also decreased dramatically post
rmIL-27 treatment. Thus, we confirmed that the thera-
peutic effect of IL-27 on CVB3-induced viral myocardi-
tis is partially attributable to the decline in Th17 cells
responses.
Conclusions
In conclusion, our preliminary data demonstrate for the
first time that IL-27 may play a myocardium-protective
role through the modulating Th17 cells responses in
CVB3-induced viral myocarditis. Therefore IL-27 may
serve as a new therapeutic candidate for treatment of
VMC. Further studies are required to comprehensively ex-
plore the therapeutic potential of IL-27 in human systems.
Materials and methods
Mice
Male specific pathogen-free BALB/c mice aged 6–8
week old were purchased from the Laboratory Animal
Center of Xi’an Jiaotong University (Shaanxi, P.R. China)
and were kept in the pathogen-free facility in the ex-
perimental animal center of the Yan’an University
(Yan’an, China). All animals received humane care ac-
cording to the criteria outlined in the “Guide for the
Care and Use of Laboratory Animals” prepared by the
National Academy of Sciences and published by the
National Institutes of Health (NIH publication 86–23
revised 1985). The study protocol was approved by the
Ethical Committee of Xianyang Hospital.
Virus
The CVB3 (Nancy strain) was maintained by passage in
HeLa cells. The viral titer was determined using a 50 %
tissue culture infectious dose (TCID50) assay on HeLa
cell monolayers and calculated by the Reed-Muench
method. BALB/c mice were infected with an intraperi-
toneal (i.p.) injection of 0.1 mL of phosphate-buffered
saline (PBS) containing 103 TCID50 of the virus for es-
tablishing VMC model. Mice administered i.p. with
PBS were taken as control.
IL-27 neutralization and overexpression
For in vivo IL-27 neutralization, mice were injected i.p.
with Mouse Anti-Mouse IL-27 p28Ab (500 μg per mouse,
MM27.7B1, BD Biosciences, San Diego, CA, USA) or con-
trol Ab (500 μg per mouse, Mouse IgG2a κ Isotype
Control, BD Biosciences, San Diego, CA, USA) on day
0 and 5 after CVB3 infection. For administration of IL-
27, mice were injected i.p. with rmIL-27 (1 μg per
mouse, BioLegend, San Diego, CA, USA) on day 0 and
5 after CVB3 infection. All surviving animals were sacri-
ficed on day 7 post CVB3 infection. The survival rates
were recorded. The hearts, spleens and plasma were col-
lected at indicated time.
Histopathological analysis and myocarditis scoring
The hearts were collected from the CVB3 infected mice
on day 7 and fixed in 10 % formalin, then embedded in
paraffin. Sections (5 μm thick) were cut and stained with
hematoxylin and eosin (H&E). Histopathological change
was observed by using light microscopy (Nikon Eclipse
E800 Microscope, Kawasaki, Kanagawa, Japan). Patho-
logical scores were graded by two independent patholo-
gists in a double-blinded manner based on the following
semi-quantitative scale: 0 = no inflammation; 1 = one to
five distinct mononuclear inflammatory foci, with the in-
volvement of 5 % or less of the cross-sectional area; 2 =
more than five distinct mononuclear inflammatory foci,
or the involvement of over 5 % but not over 20 % of the
cross-sectional area; 3 = diffuse mononuclear inflamma-
tion involving over 20 % of the area, without necrosis;
and 4 = diffuse inflammation with necrosis.
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Flow cytometry
Splenocytes from CVB3 infected mice on day 7 were iso-
lated and suspended in RPMI 1640 containing 10 % fetal
bovine serum, splenic cells were gently dispersed through
nylon mesh into a single-cell suspension. Red blood cells
were lysed by incubation for 3 min in ACK lysis buffer.
The cells were collected and resuspended at a density of
1 × 106 cell/mL. The cells were then stimulated for 4 h
with PMA (50 ng/mL) and ionomycin (500 ng/mL) in the
presence of brefeldin A (10 μg/mL) at 37 °C, 5 % CO2 in a
24-well culture plate (Corning Costar, Corning, NY, USA)
in RPMI 1640 medium supplemented with 10 % fetal bo-
vine serum. After 4 h incubation, the cells were harvested
and stained with FITC-conjugated anti-mouse CD3 anti-
body and PE- conjugated anti-mouse CD4 antibody
(BD Bioscience, San Diego, CA, USA). After the cells
were washed, fixed, and permeabilized according to
the manufacturer’s instructions (BD Bioscience, San
Diego, CA, USA), cells were stained intracellularly
with PE-Cy5.5-conjugated anti-mouse IFN-γ antibody,
and APC-conjugated anti-mouse IL-17A antibody (BD
Bioscience, San Diego, CA, USA). After incubation at
4 °C for 30 min, the samples were washed in staining
buffer and measured on a FACS-Calibur flow cyt-
ometer. The data were analyzed using FlowJo software
(Flowjo, Tree Star, Ashland, OR, USA).
Real-time PCR
Total RNA from heart tissues was extracted with TRI-
zol Reagent (Invitrogen, Gaithersburg, MD,USA), and
then converted into cDNA with M-MuLV reverse tran-
scriptase (Fermentas International Inc., Burlington, ON,
Canada) according to the manufacturer’s instructions. Real
time-polymerase chain reaction (RT-PCR) was performed
using an ABI 7500 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) using SYBR green. To
measure the viral loads in heart tissues, the total RNA
was reverse transcribed to cDNA using a CVB3-specific
positive-strand RNA primer (5’-CACCGGATGGCCAA
TCCA-3’) or a negative-strand RNA primer (5’-GCG
AAGAGTCTATTGAGCTA-3’) and then subjected to
SYBR Green real-time PCR using CVB3 primers. The
primer sequences used are shown in Table 1. The rela-
tive gene expressions were normalized to the level of β-
actin transcripts and quantified by the 2-△△CT method.
All reactions were performed in at least duplicate for
each sample.
Western blotting
About 20 μg of total protein form heart tissues was ex-
tracted and separated by 10 % SDS-PAGE, transferred
onto polyvinylidene fluoride membranes, and then
reacted with primary antibodies against Anti-IL-27RA
(1:500) and β-actin (1:1000) (all from R&D Systems,
Minneapolis, MN, USA). After being extensively washed
with PBS containing 0.1 % Triton X-100, the membranes
were incubated with alkaline phosphatase-conjugated
goat anti-rabbit antibody for 30 min at room temperature.
The bands were visualized using 1-step TM NBT/BCIP
reagents (Thermo Fisher Scientific, Rockford, IL, USA)
and detected by an Alpha Imager (Alpha Innotech, San
Leandro, CA, USA).
Cytokine ELISAs
Blood was collected via retro-orbital bleeding and serum
was separated. Freshly isolated heart tissue was ground
to a fine powder under liquid nitrogen. Each sample
(100 mg of powdered tissue) was homogenized in 0.5 mL
of RIPA buffer and then centrifuged in a cooled microcen-
trifuge for 8 min. The supernatants were then subjected to
ELISA. The amounts of IL-27, IL-17A, IFN-γ, TNF-α
and IL-6 were determined by ELISA kits (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. All samples were measured in triplicate.
Statistical analysis
All Data were presented as means ± SEM. Differences
between experimental groups were analyzed using an
unpaired Student’s t-test. Correlations were determined
by Spearman rank correlation coefficients. Survival was
estimated by the Kaplan-Meier method and compared
by the log-rank test. All data were analyzed with Graph-
Pad Prism version5.0 (GraphPad Software Inc.). P < 0.05
was considered significant difference.
Additional file
Additional file 1: Figure S1. IL-27 did not affect the body weight loss
and survival in mice not-infected with the CVB3. Male BALB/c mice were
administered i.p. with PBS at day 0; then mice were injected i.p. with
rmIL-27 or PBS on day 0 and 5 after CVB3 infection. The survival rates (A),
Table 1 Real-time PCR primers
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body weight (B) were monitored. Data are showed as the means ± SEM.
Each group contained ten mice. (TIF 819 kb)
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